ClinicalTrials.gg
Not yet recruitingNCT07951632Updated Nov 20, 2026

Allogeneic iNKT Cells in AS: Immune Remodeling Study

An observational study in Ankylosing Spondylitis, sponsored by Chinese PLA General Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Chinese PLA General Hospital · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 77 studies in Spondylitis, Ankylosing with a site in China — 20 open to participants now, 23 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Planned enrollment
15th of 15
12 · median 400
Started
2026
with 7 others
Observational
15 of 77
7 open now
Primary completion
2028-04
later than 18 of 22 live
Registered
77th of 77
by date
Lead sponsor
2 of 77
Chinese PLA General Hospital

Among the 77 studies in Spondylitis, Ankylosing with a site in China, this one is the 15th largest by planned enrollment of the 15 observational ones that give a count, is one of 8 that started in 2026, is one of 15 observational ones, reaches primary completion later than 18 of the 22 other live ones, and was the 77th registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

20 of the 77 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This study observes patients with ankylosing spondylitis (AS) who are receiving, or have received, multiple infusions of allogeneic invariant natural killer T (iNKT) cells as a treatment. Allogeneic iNKT cells are immune cells taken from a healthy donor, grown in the laboratory, and given to patients by infusion.

The treatment infusions are given under a separate treatment protocol. This study does not give any treatment. It only collects blood samples and analyzes them to learn how the immune system changes during and after the cell infusions.

Researchers will study two main questions: (1) how iNKT cell subsets and the overall immune cell network in the blood change over time, and (2) what the iNKT cells look like at the single-cell level, including their transcriptional (gene expression) profiles and clonal evolution..

Participants will provide blood samples at scheduled study visits for up to 52 weeks. The goal is to better understand how allogeneic iNKT cell therapy reshapes the immune system in AS, which may help guide future treatment studies.

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • allogeneic cell therapy
  • Immune Remodeling
  • iNKT Cells
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with a diagnosis of ankylosing spondylitis who are receiving or have received multiple infusions of allogeneic iNKT cells under a treatment protocol.Participants are enrolled from the same institution where the treatment is administered and are followed prospectively for longitudinal assessment of immune remodeling.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be able to understand the form and voluntarily agree to participate, with a signed and dated informed consent form.
  2. Age 18 to 65 years (inclusive), both sexes.
  3. Diagnosis of ankylosing spondylitis (AS) according to the 1984 modified New York criteria, and classification as axial spondyloarthritis (axSpA) according to the 2025 ASAS-SPARTAN axSpA classification criteria. Participants must have active disease, meeting both of the following criteria: (a) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4; and (b) spinal pain score >= 4 as measured by BASDAI question 2.
  4. Prior treatment with at least 2 nonsteroidal anti-inflammatory drugs (NSAIDs) at full dose on a regular schedule for at least 4 weeks, with no significant improvement in symptoms as assessed by the investigator; or intolerance to NSAIDs (discontinuation of NSAID treatment due to treatment-related adverse events, such as allergic reactions or gastrointestinal signs or symptoms; the 4-week treatment duration requirement does not apply in this case); or to NSAID treatment.
  5. Participants who have received no more than 1 prior biologic agent or JAK inhibitor (agents with the same generic name count as 1): treatment must have been administered at the recommended dose for at least 12 weeks with inadequate response, intolerance (adverse events leading to discontinuation), or inability to continue for other reasons. before the first dose: etanercept, 4 weeks; infliximab, 8 weeks; adalimumab, certolizumab pegol, or golimumab, 10 weeks; IL-17 inhibitors, 12 weeks; JAK inhibitors, 4 weeks; biologic classes not listed, 5 drug half-lives.
  6. If participants are receiving methotrexate (MTX), sulfasalazine (SSZ), or hydroxychloroquine (HCQ), the treatment duration before enrollment must be at least 3 months, and the dose must have been stable for at least 4 weeks.
  7. Participants of must use at least 1 medically accepted method during the study treatment period and for 6 months after the end of study treatment. Serum human chorionic gonadotropin (HCG) must be negative within 7 days before the first dose for women of childbearing potential; participants must be non-lactating and non-pregnant.
  8. Able to communicate well with the investigator and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Allergy to immunotherapy or to the of the drug.
  2. Known or suspected history of complete spinal ankylosis, or complete spinal ankylosis confirmed clinically and radiographically.
  3. Complete ankylosis of the sacroiliac joints.
  4. Spinal or joint surgery within 2 months before dosing, or planned spinal or joint surgery during the study period.
  5. Other untreated within the past 5 years or concomitant malignancy, except adequately treated skin basal cell carcinoma, carcinoma in situ, and breast cancer with no recurrence for more than 3 years after curative surgery.
  6. Any active, known, or suspected disease other than the indication under study (including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, vasculitis, glomerulonephritis, uveitis, hypophysitis, and hyperthyroidism). Exceptions: type 1 diabetes mellitus on stable-dose insulin therapy for at least 3 months before enrollment; hypothyroidism requiring only hormone replacement therapy; and skin conditions (such as eczema, vitiligo, or psoriasis) requiring no systemic treatment and without acute exacerbation within 1 year before screening.
  7. Severe trauma or major surgery (such as transabdominal or transthoracic surgery) within 6 months before screening, or planned major surgery during the study.
  8. History of idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis (may be enrolled if only detected on imaging and no treatment is required), or drug-induced pneumonitis.
  9. Poorly controlled cardiac signs, symptoms, or diseases: (a) congestive heart failure of class II or above; b) unstable angina within 6 months; (c) acute myocardial infarction within 1 year; (d) supraventricular or ventricular arrhythmias requiring treatment or intervention (such as > 450 msec in males or > 470 msec in females).
  10. Hypertension not well controlled by antihypertensive medication (systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg within 7 days before enrollment).
  11. Cerebrovascular or cardiovascular events within 3 months before dosing (myocardial infarction, ischemic or hemorrhagic stroke excluding lacunar infarction, deep vein thrombosis, etc.).
  12. Any of the following at screening or baseline: (a) (AST) or alanine aminotransferase (ALT) > 2.5 x ; (b) serum creatinine > 1.5 x ULN or \< 60 mL/min/1.73 m2; (c) (APTT) > 1.5 x ULN or prothrombin time (PT) > 2.5 x ULN (without anticoagulant therapy); (d) \<= 50%; (e) urine protein > 2+ on urinalysis within 7 days before enrollment, confirmed by 24-hour urine protein quantification > 1.0 g; (f) white blood cell count \< 3 x 10\^9/L, \< 90 g/L, \< 1.5 x 10\^9/L, or count \< 90 x 10\^9/L.
  13. Any of the following bleeding conditions: bleeding events of v6.0 grade 2 or above within 4 weeks before enrollment; gastrointestinal bleeding history or definite gastrointestinal bleeding within 6 months before enrollment, or bleeding from esophageal and/or gastric varices without endoscopic or transjugular intrahepatic portosystemic shunt prophylaxis; known hereditary or acquired bleeding or thrombotic tendency (such as hemophilia or coagulation disorders).
  14. Systemic active infection requiring treatment within 2 weeks before enrollment, or unexplained fever with temperature >= 38.5 degrees C within 7 days before enrollment.
  15. Congenital or acquired immunodeficiency (such as infection); active syphilis infection; positive tuberculosis test.
  16. or infection at screening with viral load above the lower limit of detection (HBV DNA >= 10 IU/mL or HCV RNA >= 10 IU/mL).
  17. Prior receipt of genetically modified cell therapy, or receipt of non-genetically modified cell therapy within 6 months before screening.
  18. Prior use of oral glucocorticoids, or receipt of glucocorticoids by any intra-articular, intramuscular, or intravenous injection.
  19. Receipt of disease-modifying antirheumatic drugs (DMARDs) other than sulfasalazine and hydroxychloroquine within 1 month before dosing; leflunomide discontinued for less than 8 weeks; or discontinuation for less than 5 drug half-lives according to the actual drug class (i.e., the DMARD should exceed 5 half-lives of the corresponding drug), whichever is longer.
  20. Current use of strong opioid analgesics (such as methadone, hydromorphone, or morphine).
  21. Vaccination with live or attenuated vaccines within 4 weeks before screening.
  22. Enrollment in another clinical study of a drug or device within 4 weeks before screening.
  23. Other factors judged by the investigator that may lead to premature study termination, such as other serious concomitant diseases (including severe diabetes, thyroid disease, spinal cord compression, superior vena cava syndrome, or psychiatric illness), severe laboratory abnormalities, or family or social factors that may affect participant safety or the collection of data and samples.
  24. Intolerance to venipuncture, or history of needle or blood phobia.
  25. History of alcoholism, drug abuse, or use of any illicit drugs.
  26. Other factors considered by the investigator to be unsuitable for enrollment or likely to affect participant participation or completion of the study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ankylosing Spondylitis Cohort

    Patients with ankylosing spondylitis who are receiving or have received multiple infusions of allogeneic invariant natural killer T (iNKT) cells under a treatment protocol. Participants are followed prospectively for assessment of immune remodeling.

    Biological: Allogeneic iNKT Cells

Interventions

  • BiologicalAllogeneic iNKT Cells

    Ex vivo expanded allogeneic invariant natural killer T (iNKT) cells administered by infusion under a separate treatment protocol. This study observes participants receiving this treatment; infusions are not administered by this observational study. Data collected include peripheral blood immune cell phenotyping and single-cell transcriptomic analysis to assess immune remodeling.

06

What researchers measure

Primary outcomes

  1. Change in Peripheral Blood iNKT Cell Subset Polarization During Multiple Infusions of Allogeneic iNKT Cells

    Time frame: Up to 52 weeks

  2. Change in Peripheral Blood Immune Network Remodeling During Multiple Infusions of Allogeneic iNKT Cells

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Single-Cell Transcriptomic Signatures of iNKT Cells During Multiple Infusions of Allogeneic iNKT Cells

    Time frame: Up to 52 weeks

  2. Clonal Evolution of iNKT Cells During Multiple Infusions of Allogeneic iNKT Cells

    Time frame: Up to 52 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

Of 47 non-industry observational studies under Spondylitis, Ankylosing, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 201. This study's planned 17 months is below that.

Counting every sponsor, half of 80 studies reached it within 47 months; a quarter within 27 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2026
Primary completionEst.
Apr 16, 2028
CompletionEst.
Apr 16, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951632
Responsible party
Jian Zhu (Professor and Chief Physician, Chinese PLA General Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Apr 16, 2028 (estimated)
Completion
Apr 16, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Jian Zhu, MD
Contact
Jian_jzhu@126.com
+86-10-55499314

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion